Amarantus Bioscience (AMBS) Stock Price, News & Analysis

Company Overview

Amarantus Bioscience Holdings, Inc. is a development‐stage biotechnology company focused on the discovery and development of diagnostic and therapeutic products for neurodegenerative diseases. The company’s pipeline includes Eltoprazine, a serotonergic agent in clinical trials for the treatment of levodopa‐induced dyskinesia in Parkinson’s disease, and recombinant human mesencephalic astrocyte‐derived neurotrophic factor (MANF) for potential applications in neuroprotection. Leveraging both small molecule and biologic platforms, Amarantus aims to address unmet medical needs in Parkinson’s disease, Alzheimer’s disease and traumatic brain injury.

In addition to its therapeutic programs, Amarantus operates a diagnostics division dedicated to the identification of biomarkers for central nervous system injuries and mild cognitive impairment. The company’s diagnostic initiatives include blood‐based assays and imaging approaches designed to support early detection, patient stratification and treatment monitoring. These tools are intended to complement its drug development activities and facilitate clinical decision‐making in both neurology and sports medicine.

Headquartered in Emeryville, California, Amarantus conducts clinical trials and research collaborations across North America and Europe. The company is led by a management team with deep expertise in drug development, regulatory strategy and commercialization. Steven C. Quay, MD, PhD, serves as chairman, guiding corporate strategy while the senior leadership focuses on advancing the pipeline toward regulatory milestones and potential partnerships.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMBS Stock Analysis - Frequently Asked Questions

How do I buy shares of Amarantus Bioscience?

Shares of AMBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amarantus Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarantus Bioscience investors own include Aurora Cannabis (ACB), B2Gold (BTG), CEA Industries (CEAD), Fortune Minerals (FTMDF), Kutcho Copper (KCCFF), Liberty Star Uranium & Metals (LBSR) and Liberty Gold (LGDTF).

Company Calendar

• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AMBS
• CIK: 1424812
• Web: www.amarantus.com
• Phone: (650) 862-5391
• Fax: 408-852-4427
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.57